drugset
Drugs / Tumor-specific ex vivo expanded autologous lymphocyte transfer
last change Sep 2021 re-read 3 minutes ago

Tumor-specific ex vivo expanded autologous lymphocyte transfer

also known as TTRNA-xALT

Cell therapy

Developed for
diffuse intrinsic pontine glioma · neuroblastoma
Investigated by
Beat Childhood Cancer Research Consortium · University of Florida

Trials 1

today NCT04837547 · Ph 1
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04837547 Sep 2021 → Sep 2027 expected diffuse intrinsic pontine glioma, neuroblastoma University of Florida Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Tumor-specific ex vivo expanded autologous lymphocyte transfer ClinicalTrials.gov intervention name — accepted as the source's own label NCT04837547 ↗
Known as TTRNA-xALT “Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)” NCT04837547 ↗
Modality Cell therapy “adoptive cell therapy” NCT04837547 ↗